Neurocrine's Blockbuster Assembly Line: VYKAT XR Joins the Portfolio

Record Q2 revenue and a transformative $2.9B acquisition, but the market is still pricing in IRA and integration risk

NBIX · Earnings Call · 2026-07-30

A Record Quarter, Three Engines

Neurocrine's second quarter 2026 was a showcase of its deliberate transformation from a single-product biotech into a diversified commercial powerhouse. “For the second quarter, we delivered over $950 million of total revenue, representing nearly 40% year over year growth.” — Matthew C. Abernethy, Chief Financial Officer · 2026-07-30 That growth was powered by three first-in-class medicines: INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. The company's commercial portfolio now annualizes to roughly $4 billion, and management raised full-year INGREZZA guidance to $2.825–$2.875 billion. Total Revenue reached $814M in Q1 2026 (latest 10-Q), a +42% YoY jump, and Q2 pro forma revenue of $998M underscores the accelerated momentum.

VYKAT XR: The Acquisition That Changes the Narrative

The headline event was the close of the Soleno acquisition on May 18, giving Neurocrine full control of VYKAT XR, the first-in-disease treatment for Prader-Willi syndrome.

We acquired So for approximately $2.9 billion and financed the transaction with cash on hand.
Matthew C. Abernethy, Chief Financial Officer · 2026-07-30

The company ended the quarter with ~$500M in cash and no debt—a discipline that CFO Matthew Abernethy emphasized. Management is careful to set expectations for the integration. The product contributed only $54M recognized in Q2 (pro forma $94M), and new patient starts have been steady but flat. “We have only had the product for 6 weeks. It is a market that we are incredibly excited about.” — Matthew C. Abernethy, Chief Financial Officer · 2026-07-30 Discontinuations, particularly from the initial launch bolus, are expected to settle into the 25–30% orphan-medicine range, with sequential growth resuming in Q4. The company is leveraging its commercial infrastructure to expand the prescriber base and drive sequential growth as it exits 2026.

Pipeline: The Next Chapter

Beyond the commercial momentum, Neurocrine's pipeline is advancing with two Phase 3 readouts due in 2027: osavampator in major depressive disorder and dereclidine in schizophrenia. Chief Medical Officer Sanjay Keswani confirmed: “We remain on track to report phase 3 top line data for osavampator in major depressive disorder in the second half of 27.” — Sanjay Keswani MBBS, Chief Medical Officer · 2026-07-30 The company is also building a muscarinic franchise with four shots on goal, and an obesity program anchored by a CRF2 agonist (NBI-112) expected to yield signal-seeking data next year. This pipeline breadth marks a deliberate pivot. As CEO Kyle Gano noted, the company is diversifying risk across therapeutic areas, balancing neuropsych with obesity and endocrinology. The dereclidine program, in particular, is positioned to differentiate on safety and tolerability—a key advantage highlighted by the Maplight data readout.

Market Skepticism Persists

Despite the strong quarter, the stock has pulled back 17.8% from its July 30 peak, touching $185.50 that day. This divergence suggests investors remain cautious about the 2029 IRA implementation for INGREZZA, the largest revenue driver. Management acknowledges the risk but points to a sticky patient base and a growing market. On the competitive front, they note INGREZZA continues to outgrow the VMAT2 category and maintains preferred coverage. The company's transformation is real, but the market is waiting for proof of sustainable growth beyond the VYKAT acquisition. As one prior call emphasized, it took years to build confidence in guidance. The coming quarters—and the 2027 data catalysts—will determine whether Neurocrine can maintain its multi-blockbuster trajectory.